Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1379419 | 0.99 | HTR6 (0.47) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3622734 | 0.91 | HTR6 (0.55) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| Hydrochloric Acid SCHEMBL1377178 | 0.90 | HTR6 (0.54) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3620792 | 0.89 | HTR6 (0.54) | HTR6 | |
| SCHEMBL3620585 | 0.86 | HTR6 (0.49) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3618637 | 0.85 | HTR6 (0.53) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3619305 | 0.85 | HTR6 (0.53) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3614437 | 0.82 | HTR6 (0.50) | HTR6HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3617406 | 0.82 | HTR6 (0.60) | HTR6 | |
| SCHEMBL1062855 | 0.81 | LMNA (0.51) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HTR6 1659/4885HTR1A 2063/4885HTR1D 3212/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR6 1213/4885HTR1A 1937/4885HTR1D 3296/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | HTR6 2369/4885HTR1A 1888/4885HTR1D 2785/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | HTR6 1213/4885HTR1A 1937/4885HTR1D 3296/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | HTR6 1659/4885HTR1A 2063/4885HTR1D 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.